Washington University School of Medicine
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Inclusion Criteria: * Diagnosis of recurrent, FIGO grade 3 endometrioid, serous, or mixed high grade uterine or endometrial cancer or uterine carcinosarcoma. Patients must have experienced either prior progression on a platinum-based therapy or intolerance to platinum. Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents. * 1-2 prior lines of anti-cancer therapy are allowed. * Subjects who have received prior treatment with trastuzumab, pembrolizumab, or dostarlimab can enroll in the study. Use of these…
Taken by mouth.
175 mg\^m2 intravenous over 3 hours.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.